z-logo
open-access-imgOpen Access
Clinical findings from the landmark MEF2C ‐related disorders natural history study
Author(s) -
Cooley Coleman Jessica A.,
Sarasua Sara M.,
Moore Hannah Warren,
Boccuto Luigi,
Cowan Christopher W.,
Skinner Steven A.,
DeLuca Jane M.
Publication year - 2022
Publication title -
molecular genetics and genomic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.765
H-Index - 29
ISSN - 2324-9269
DOI - 10.1002/mgg3.1919
Subject(s) - medicine , clinical psychology , psychology
MEF2C ‐related disorders are characterized by developmental and cognitive delay, limited language and walking, hypotonia, and seizures. A recent systematic review identified 117 patients with MEF2C ‐related disorders across 43 studies. Despite these reports, the disorder is not easily recognized and assessments are hampered by small sample sizes. Our objective was to gather developmental and clinical information on a large number of patients. Methods We developed a survey based on validated instruments and subject area experts to gather information from parents of children with this condition. No personal identifiers were collected. Surveys and data were collected via REDCap and analyzed using Excel and SAS v9.4. Results Seventy‐three parents completed the survey, with 39.7% reporting a MEF2C variant and 54.8% reporting a deletion involving MEF2C . Limited speech (82.1%), seizures (86.3%), bruxism (87.7%), repetitive movements (94.5%), and high pain tolerance (79.5%) were some of the prominent features. Patients with MEF2C variants were similarly affected as those with deletions. Female subjects showed higher verbal abilities. Conclusion This is the largest natural history study to date and establishes a comprehensive review of developmental and clinical features for MEF2C ‐related disorders. This data can help providers diagnose patients and form the basis for longitudinal or genotype–phenotype studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here